GAMA
AGIO icon

Graticule Asia Macro Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Graticule Asia Macro Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-12,500
Closed -$522K – 124
2016
Q4 		$522K Buy
+12,500
New +$656K 0.06% 91

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Graticule Asia Macro Advisors's AGIO Position: Q3 2016 in Review

Graticule Asia Macro Advisors sold out of Agios Pharmaceuticals (AGIO) in Q3 2016, closing a stake of 19,900 shares — an estimated $834K sold.

Graticule Asia Macro Advisors first reported a position in AGIO in Q2 2016 and held it in 1 quarter. The position peaked at $834K in Q2 2016. 163 funds tracked by Wall St. Rank hold AGIO as of Q3 2016.

  • Graticule Asia Macro Advisors reported no remaining Agios Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Graticule Asia Macro Advisors sold 19,900 Agios Pharmaceuticals shares in Q3 2016, an estimated $834K.
  • Graticule Asia Macro Advisors first reported a position in Agios Pharmaceuticals in Q2 2016 and held it in 1 quarter.
  • Graticule Asia Macro Advisors's Agios Pharmaceuticals position peaked at $834K in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2016.

Based on Graticule Asia Macro Advisors's 13F filing for Q3 2016, filed 14 Nov 2016.